Investors



Investor Relations

Stock price graph
             

We are developing a platform of a new class of broad-spectrum catalytic antioxidant compounds based on technology discovered at Duke University and National Jewish Health. Our strategy is to use non-dilutive capital wherever possible to develop our exciting platform of broad-spectrum catalytic antioxidant compounds in important unmet indications of national strategic importance. We plan to continue to leverage that capital, like the investment made by U.S. government agencies, such as NIH-NIAID and NIH CounterACT, in AEOL 10150 as a medical countermeasure, to concurrently develop these promising compounds for use in significant unmet medical indications, like oncology.


Recent Releases

Jun 8, 2017
Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event

May 15, 2017
Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017

View all releases »